EUCTR2009-012280-34-DE进行中（未招募）不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- •Histologically confirmed non-GCB, de novo DLBCL
- •– The histological confirmation of non-GCB DLBCL must be done centrally.
- •Paraffin-embedded tissue blocks must be sent to the central laboratory for
- •confirmation of the non-GCB subtype by IHC prior to randomization
- •– CD20+ disease
- •Stage II, III, or IV disease by the American Joint Committee on Cancer, NHL staging
- •system. Stage 1 primary mediastinal (thymic) DLBCL is also eligible.
- •At least 1 measurable site of disease based on the Revised Response Criteria for Malignant Lymphoma
- •Man or women, aged 18 years or older (must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place.)
- •Eastern Cooperative Oncology Group [ECOG] performance status of 0, 1, or 2
- •Absolute neutrophil count (ANC) =1,500 cells/µL
- •Platelets =100,000 cells/µL. Subjects with thrombocytopenia due to bone marrow
- •infiltration from DLBCL are eligible if platelets are =50,000 cells/µL.
- •Alanine aminotransferase (ALT) =3 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) =3 x ULN
- •Total bilirubin <2mg/dL, except in patients with Gilbert syndrome or in patients in
- •whom the bilirubin rise is of non-hepatic origin
- •Serum creatinine <1.5 x ULN or creatinine clearance =50 cc/min
- •Women must be:
- •– postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months),
- •– surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
- •ligation, or otherwise be incapable of pregnancy),
- •– abstinent (at the discretion of the investigator/per local regulations), or
- •– if sexually active, be practicing a highly effective method of birth control
- •(eg, prescription oral contraceptives, contraceptive injections, contraceptive patch,
- •intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical
- •cap, with spermicidal foam, cream, or gel, male partner sterilization) as local
- •regulations permit, before entry, and must agree to continue to use the same
- •method of contraception throughout the study. They must also be prepared to
- •continue birth control measures for at least 12 months after terminating treatment.
- •Women of childbearing potential must have a negative serum or urine ß-human
- •chorionic gonadotropin (ß-hCG) pregnancy test at screening
- •Men must agree to use an acceptable method of contraception (for themselves or
- •female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug
- •Willing/able to adhere to the prohibitions and restrictions specified in this protocol
- •All subjects (or their legally-acceptable representatives) must have signed an
- •informed consent document indicating that they understand the purpose of and
- •procedures required for the study and are willing to participate in the study
- •To participate in the optional pharmacogenomic component of this study, subjects (or their legally-acceptable representative) must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the
- •pharmacogenomic component of the study (where local regulations permit). Refusal
- •to give consent for this component does not exclude a subject from participation in
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from
- •participating in the study:
- •History of disallowed therapies:
- •Prior treatment with VELCADE
- •Transformed lymphomas (follicular, T-cell, or Hodgkin’s lymphoma)
- •Prior extended radiotherapy for lymphoma (extended field radiotherapy such as
- •mantle field radiation and inverted Y field radiation)
- •More than 150 mg/m2 of prior doxorubicin for any reason
- •Major surgery within 3 weeks before randomization
- •Prior chemotherapy for lymphoma
- •Short course (maximum of 10 days; not exceeding 100 mg/day) prednisone or equivalent steroids are allowed to treat symptoms in subjects with advanced disease who entered the screening phase and are waiting to be randomized.
- •Peripheral neuropathy or neuralgia of Grade 2 or worse
- •Active CNS lymphoma
- •Pregnant or breast feeding
- •Uncontrolled or severe cardiovascular disease, including myocardial infarction within
- •6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart
- •failure, uncontrolled angina, pericardial disease, cardiac amyloidosis,
- •or left ventricular ejection fraction (LVEF) <45%
- •Diagnosed or treated for a malignancy other than NHL except: adequately treated
- •non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, ductal
- •carcinoma in situ of the breast, or other solid tumors curatively treated with no
- •evidence of disease for >5 years
- •Active systemic infection requiring treatment including active hepatitis B infection
- •(carriers of hepatitis B are permitted to enter the study)
- •Documented or suspected human immunodeficiency virus (HIV)/AIDS
- •Known allergies, hypersensitivity, or intolerance to VELCADE, cyclophosphamide,
- •rituximab, prednisone, doxorubicin, vincristine, or its excipients or compounds containing boron, mannitol, or similar agents
- •Serious medical condition, such as active peptic ulcer disease, acute diffuse
- •interstitial pulmonary disease, uncontrolled diabetes, or psychiatric illness, likely to
- •interfere with participation in this clinical study
- •Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is not excluded.
- •Any condition that, in the opinion of the investigator, would compromise the
- •well-being of the subject or the study or prevent the subject from meeting or
- •performing study requirements
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell LymphomaEUCTR2009-012280-34-CZJanssen-Cilag International N.V.164
已完成
2 期
A clinical trial to study the effects of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCTRI/2009/091/000929Janssen Research Development LLC164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphomaon-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 14.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012280-34-BEJanssen-Cilag International N.V.164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia - Lumiliximab in combination with FCR in the treatment of relapsed CRelapsed Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008956Term: Chronic lymphatic leukaemiaEUCTR2006-002987-24-FRBiogen Idec Ltd280
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia - Lumiliximab in combination with FCR in the treatment of relapsed CRelapsed Chronic Lymphocytic Leukemia (CLL)MedDRA version: 8.1Level: LLTClassification code 10008956Term: Chronic lymphatic leukaemiaEUCTR2006-002987-24-PTBiogen Idec Ltd627